2024 Q2 Form 10-Q Financial Statement

#000193341424000016 Filed on May 09, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1 2023 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.895M $4.608M $4.026M
YoY Change 53.08% 74.22% 83.84%
% of Gross Profit
Research & Development $39.27M $30.75M $23.69M
YoY Change 230.47% 150.17% 202.95%
% of Gross Profit
Depreciation & Amortization $9.000K $8.000K
YoY Change
% of Gross Profit
Operating Expenses $45.17M $35.36M $27.71M
YoY Change 187.05% 136.73% 176.89%
Operating Profit -$45.17M -$35.36M
YoY Change 187.05% 136.73%
Interest Expense $4.152M $3.853M $3.321M
YoY Change 15.56% 65.44% 255.19%
% of Operating Profit
Other Income/Expense, Net $4.154M $3.854M $1.000K
YoY Change 15.58% 65.41%
Pretax Income -$41.01M -$31.51M -$24.39M
YoY Change 237.81% 149.9% 168.81%
Income Tax
% Of Pretax Income
Net Earnings -$41.01M -$31.50M -$24.39M
YoY Change 237.81% 150.0% 168.81%
Net Earnings / Revenue
Basic Earnings Per Share -$0.83 -$0.70
Diluted Earnings Per Share -$0.83 -$0.70 -$0.61
COMMON SHARES
Basic Shares Outstanding 49.65M shares 49.63M shares 41.11M shares
Diluted Shares Outstanding 49.36M shares 44.90M shares

Balance Sheet

Concept 2024 Q2 2024 Q1 2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $311.1M $338.6M $236.6M
YoY Change 19.16% 25.1% 114.85%
Cash & Equivalents $67.86M $90.42M $49.30M
Short-Term Investments $243.3M $248.1M $187.3M
Other Short-Term Assets $6.886M $8.254M $12.54M
YoY Change -17.94% 78.08% 364.12%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $318.0M $346.8M $249.1M
YoY Change 18.0% 25.99% 120.81%
LONG-TERM ASSETS
Property, Plant & Equipment $42.00K $51.00K $0.00
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $0.00 $2.482M
YoY Change -100.0% -100.0%
Other Assets $449.0K $379.0K $51.00K
YoY Change 780.39% 871.79% -96.87%
Total Long-Term Assets $491.0K $430.0K $2.533M
YoY Change -97.74% -98.62% 55.3%
TOTAL ASSETS
Total Short-Term Assets $318.0M $346.8M $249.1M
Total Long-Term Assets $491.0K $430.0K $2.533M
Total Assets $318.5M $347.2M $251.6M
YoY Change 9.37% 13.32% 119.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.707M $4.261M $601.0K
YoY Change -22.27% 78.51% -68.48%
Accrued Expenses $26.69M $14.94M $9.881M
YoY Change 565.42% 82.83% 79.3%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $28.40M $19.20M $10.48M
YoY Change 357.5% 81.86% 29.94%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $28.40M $19.20M $10.48M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $28.40M $19.20M $10.48M
YoY Change 357.5% 81.86% 29.94%
SHAREHOLDERS EQUITY
Retained Earnings -$197.2M -$156.2M -$124.7M
YoY Change 154.12% 138.84% 136.13%
Common Stock $5.000K $5.000K $4.000K
YoY Change 25.0% 25.0% 300.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $290.1M $328.0M $241.2M
YoY Change
Total Liabilities & Shareholders Equity $318.5M $347.2M $251.6M
YoY Change 9.37% 13.32% 119.88%

Cashflow Statement

Concept 2024 Q2 2024 Q1 2023 Q4
OPERATING ACTIVITIES
Net Income -$41.01M -$31.50M -$24.39M
YoY Change 237.81% 150.0% 168.81%
Depreciation, Depletion And Amortization $9.000K $8.000K
YoY Change
Cash From Operating Activities -$30.15M -$19.10M -$28.98M
YoY Change 47.88% 49.22% 184.52%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $59.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $7.736M -$55.89M -$8.089M
YoY Change -147.93% -60.15% -116.18%
Cash From Investing Activities $7.736M -$55.95M -$8.089M
YoY Change -147.93% -60.11% -116.18%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -152.0K $116.2M 74.00K
YoY Change -73.84% -42.92% -106.93%
NET CHANGE
Cash From Operating Activities -30.15M -$19.10M -28.98M
Cash From Investing Activities 7.736M -$55.95M -8.089M
Cash From Financing Activities -152.0K $116.2M 74.00K
Net Change In Cash -22.56M $41.11M -37.00M
YoY Change -39.2% -18.66% -195.48%
FREE CASH FLOW
Cash From Operating Activities -$30.15M -$19.10M -$28.98M
Capital Expenditures $0.00 $59.00K
Free Cash Flow -$30.15M -$19.16M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.0926
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4608000 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2645000 usd
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
35362000 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
14938000 usd
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-35362000 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-14938000 usd
CY2024Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
3853000 usd
CY2023Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
2329000 usd
CY2024Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
1000 usd
CY2023Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
1000 usd
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3854000 usd
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2330000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-31508000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-12608000 usd
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.70
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.70
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.51
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.51
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44900755 shares
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44900755 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24764469 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24764469 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-52269000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
158644000 usd
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
201359000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
749000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-12608000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
295875000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
241154000 usd
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
116059000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
149000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2191000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-31508000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
328045000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-31508000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-12608000 usd
CY2024Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
2509000 usd
CY2023Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
855000 usd
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2191000 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
749000 usd
CY2024Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
8000 usd
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
0 usd
CY2024Q1 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-119000 usd
CY2023Q1 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
270000 usd
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-4159000 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1703000 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
8401000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1912000 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19139000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12775000 usd
CY2024Q1 us-gaap Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
123393000 usd
CY2023Q1 us-gaap Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
162751000 usd
CY2024Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities
67500000 usd
CY2023Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities
22500000 usd
CY2024Q1 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
59000 usd
CY2023Q1 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
0 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-55952000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-140251000 usd
CY2024Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
116119000 usd
CY2023Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
0 usd
CY2024Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
149000 usd
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 usd
CY2024Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
63000 usd
CY2023Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 usd
CY2024Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0 usd
CY2023Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
203571000 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
116205000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
203571000 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
41114000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
50545000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
49304000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
87701000 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
90418000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
138246000 usd
CY2024Q1 mlys Offering Costs Incurred During Noncash Or Partial Noncash Transaction
OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction
321000 usd
CY2023Q1 mlys Offering Costs Incurred During Noncash Or Partial Noncash Transaction
OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction
581000 usd
CY2024Q1 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
0 usd
CY2023Q1 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
159180000 usd
CY2024Q1 us-gaap Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss
DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss
248100000 usd
CY2024Q1 us-gaap Investments And Cash
InvestmentsAndCash
338600000 usd
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-156200000 usd
CY2024Q1 us-gaap Investments And Cash
InvestmentsAndCash
338600000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-31500000 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19100000 usd
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
498800000 usd
CY2024Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates </span></div>The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ from those estimates. Estimates have been used in the following areas, among others: research and development accruals, fair value of the Company’s common stock prior to the closing of the Company’s IPO, and income taxes.
CY2024Q1 us-gaap Restricted Cash
RestrictedCash
0 usd
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
0 usd
CY2024Q1 us-gaap Cash
Cash
5376000 usd
CY2023Q4 us-gaap Cash
Cash
643000 usd
CY2024Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
85042000 usd
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
48661000 usd
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
90418000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49304000 usd
CY2024Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of Credit Risk </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has no significant off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts, or other hedging arrangements. Financial instruments that </span></div>potentially subject the Company to concentrations of credit risk primarily consist of cash balances in several accounts with three financial institutions which, from time to time, are in excess of federally insured limits.
CY2024Q1 us-gaap Deferred Offering Costs
DeferredOfferingCosts
300000 usd
CY2023Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
0 usd
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
749000 usd
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
true
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5219286 shares
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3670597 shares
CY2024Q1 us-gaap Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss
DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss
248147000 usd
CY2024Q1 us-gaap Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
248050000 usd
CY2023Q4 us-gaap Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss Current
DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent
187263000 usd
CY2023Q4 us-gaap Debt Securities Held To Maturity Fair Value Current
DebtSecuritiesHeldToMaturityFairValueCurrent
187293000 usd
CY2023Q4 us-gaap Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss Noncurrent
DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossNoncurrent
2482000 usd
CY2023Q4 us-gaap Debt Securities Held To Maturity Fair Value Noncurrent
DebtSecuritiesHeldToMaturityFairValueNoncurrent
2486000 usd
CY2023Q4 us-gaap Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss
DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss
189745000 usd
CY2023Q4 us-gaap Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
189779000 usd
CY2024Q1 mlys Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
12857000 usd
CY2023Q4 mlys Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
7122000 usd
CY2024Q1 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
662000 usd
CY2023Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1599000 usd
CY2024Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1424000 usd
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1160000 usd
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14943000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9881000 usd
CY2024Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
8584725 shares
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q1 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
50000000 shares
CY2024Q1 mlys Sale Of Warrants Number Of Shares Issued In Transaction
SaleOfWarrantsNumberOfSharesIssuedInTransaction
549755 shares
CY2024Q1 mlys Sale Of Warrants Price Per Share
SaleOfWarrantsPricePerShare
13.499
CY2024Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.001
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4251075 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2981285 shares
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2191000 usd

Files In Submission

Name View Source Status
0001933414-24-000016-index-headers.html Edgar Link pending
0001933414-24-000016-index.html Edgar Link pending
0001933414-24-000016.txt Edgar Link pending
0001933414-24-000016-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
mlys-1q2410qex311.htm Edgar Link pending
mlys-1q2410qex312.htm Edgar Link pending
mlys-1q2410qex321.htm Edgar Link pending
mlys-1q2410qex322.htm Edgar Link pending
mlys-20240331.htm Edgar Link pending
mlys-20240331.xsd Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
R1.htm Edgar Link pending
mlys-20240331_def.xml Edgar Link unprocessable
mlys-20240331_pre.xml Edgar Link unprocessable
mlys-20240331_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable
mlys-20240331_cal.xml Edgar Link unprocessable
mlys-20240331_lab.xml Edgar Link unprocessable